Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

Chung Feng Huang; Jee Fu Huang; Jeng Fu Yang; Ming Yen Hsieh; Zu Yau Lin; Shinn Cherng Chen; Liang Yen Wang; Suh Hang Hank Juo; Ku Chung Chen; Wan Long Chuang; Hsing Tao Kuo; Chia Yen Dai; Ming Lung Yu

doi:10.1016/j.jhep.2011.03.029

Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

Chung Feng Huang, Jee Fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, Liang Yen Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan Long Chuang, Hsing Tao Kuo, Chia Yen Dai, Ming Lung Yu

研究成果: 雜誌貢獻 › 文章 › 同行評審

75 引文斯高帕斯（Scopus）

摘要

Background & Aims: A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24 weeks of post-treatment follow-up) after 24 weeks peginterferon/ribavirin therapy. We explored the role of interleukin-28B genotype in identifying patients who responded to the regimen. Methods: Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks peginterferon/ribavirin. Results: Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p

原文	英語
頁（從 - 到）	34-40
頁數	7
期刊	Journal of Hepatology
卷	56
發行號	1
DOIs	https://doi.org/10.1016/j.jhep.2011.03.029
出版狀態	已發佈 - 1月 2012
對外發佈	是

ASJC Scopus subject areas

肝病

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.1016/j.jhep.2011.03.029

其它文件與鏈接

Link to publication in Scopus

引用此

Huang, C. F., Huang, J. F., Yang, J. F., Hsieh, M. Y., Lin, Z. Y., Chen, S. C., Wang, L. Y., Juo, S. H. H., Chen, K. C., Chuang, W. L., Kuo, H. T., Dai, C. Y., & Yu, M. L. (2012). Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. Journal of Hepatology, 56(1), 34-40. https://doi.org/10.1016/j.jhep.2011.03.029

Huang, CF, Huang, JF, Yang, JF, Hsieh, MY, Lin, ZY, Chen, SC, Wang, LY, Juo, SHH, Chen, KC, Chuang, WL, Kuo, HT, Dai, CY & Yu, ML 2012, 'Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin', Journal of Hepatology, 卷 56, 編號 1, 頁 34-40. https://doi.org/10.1016/j.jhep.2011.03.029

@article{922973403ac24eb68ebadacfbcf59c40,

title = "Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin",

abstract = "Background & Aims: A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24 weeks of post-treatment follow-up) after 24 weeks peginterferon/ribavirin therapy. We explored the role of interleukin-28B genotype in identifying patients who responded to the regimen. Methods: Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks peginterferon/ribavirin. Results: Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p ",

keywords = "HCV, IL-28B, Tailored regimen, Treatment",

author = "Huang, {Chung Feng} and Huang, {Jee Fu} and Yang, {Jeng Fu} and Hsieh, {Ming Yen} and Lin, {Zu Yau} and Chen, {Shinn Cherng} and Wang, {Liang Yen} and Juo, {Suh Hang Hank} and Chen, {Ku Chung} and Chuang, {Wan Long} and Kuo, {Hsing Tao} and Dai, {Chia Yen} and Yu, {Ming Lung}",

year = "2012",

month = jan,

doi = "10.1016/j.jhep.2011.03.029",

language = "English",

volume = "56",

pages = "34--40",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

AU - Huang, Chung Feng

AU - Huang, Jee Fu

AU - Yang, Jeng Fu

AU - Hsieh, Ming Yen

AU - Lin, Zu Yau

AU - Chen, Shinn Cherng

AU - Wang, Liang Yen

AU - Juo, Suh Hang Hank

AU - Chen, Ku Chung

AU - Chuang, Wan Long

AU - Kuo, Hsing Tao

AU - Dai, Chia Yen

AU - Yu, Ming Lung

PY - 2012/1

Y1 - 2012/1

N2 - Background & Aims: A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24 weeks of post-treatment follow-up) after 24 weeks peginterferon/ribavirin therapy. We explored the role of interleukin-28B genotype in identifying patients who responded to the regimen. Methods: Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks peginterferon/ribavirin. Results: Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p

AB - Background & Aims: A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24 weeks of post-treatment follow-up) after 24 weeks peginterferon/ribavirin therapy. We explored the role of interleukin-28B genotype in identifying patients who responded to the regimen. Methods: Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks peginterferon/ribavirin. Results: Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p

KW - HCV

KW - IL-28B

KW - Tailored regimen

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=83555174789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555174789&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2011.03.029

DO - 10.1016/j.jhep.2011.03.029

M3 - Article

C2 - 21703176

AN - SCOPUS:83555174789

SN - 0168-8278

VL - 56

SP - 34

EP - 40

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 1

ER -

Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

摘要

ASJC Scopus subject areas

UN SDG

存取文件

其它文件與鏈接

指紋

引用此